Gainers
- ADMA Biologics ADMA shares moved upwards by 11.42% to $1.56 during Thursday's pre-market session. The market value of their outstanding shares is at $305.4 million. As per the press release, Q3 earnings came out yesterday.
- Dynatronics DYNT shares rose 9.33% to $1.64. The company's market cap stands at $28.8 million. As per the news, the Q1 earnings report came out today.
- Erytech Pharma ERYP shares increased by 8.69% to $2.5. The company's market cap stands at $69.8 million.
- AnPac Bio-Medical Science ANPC stock moved upwards by 8.28% to $1.7. The market value of their outstanding shares is at $23.9 million.
- Repro-Med Systems KRMD stock rose 8.15% to $3.05. The market value of their outstanding shares is at $135.7 million. As per the press release, Q3 earnings came out yesterday.
- UpHealth UPH shares moved upwards by 7.37% to $2.62. The market value of their outstanding shares is at $368.8 million. The company's, Q3 earnings came out yesterday.
Losers
- Schrodinger SDGR shares decreased by 15.37% to $43.3 during Thursday's pre-market session. The market value of their outstanding shares is at $3.0 billion. As per the press release, Q3 earnings came out yesterday.
- Cumberland CPIX shares declined by 8.69% to $2.63. The company's market cap stands at $39.1 million. As per the news, the Q3 earnings report came out 2 days ago.
- Progenity PROG stock fell 8.53% to $3.22. The company's market cap stands at $427.4 million. The company's, Q3 earnings came out yesterday.
- FIGS FIGS stock declined by 7.65% to $36.0. The market value of their outstanding shares is at $5.7 billion. As per the press release, Q3 earnings came out yesterday.
- Calliditas Therapeutics CALT stock declined by 7.21% to $16.75. The company's market cap stands at $438.3 million.
- MorphoSys MOR shares declined by 4.81% to $10.49. The market value of their outstanding shares is at $1.4 billion. As per the press release, Q3 earnings came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in